Results 231 to 240 of about 75,785 (301)

Optimal conditions for quantification of IRF4 mRNA and protein as a correlative biomarker in clinical cancer studies. [PDF]

J Transl Med
Hartman JD, Vicenzi S, Tong AA, Avsharian LC, Vora AA, Costello C, Deichaite I, Crews LA.   +7 more
europepmc   +1 more source

Limited roles of the miR‐17‐92 cluster in the regulation of T‐cell apoptosis

The FEBS Journal, EarlyView.
The pro‐apoptotic protein BIM shapes T‐cell survival and function, but how it is regulated remains unclear. In a mouse model lacking direct miR‐17‐92:Bim interactions, we observed a moderate reduction in Th17 CD4+ T cells. BIM levels were modestly increased in double‐positive thymocytes and naive CD8+ T cells, but this did not affect overall T‐cell ...
Katharina Hoppe, Johannes Woelk, Julia Benz, Sarah Spoeck, William J. Olson, Andreas Villunger, Natascha Hermann‐Kleiter, Verena Labi   +7 more
wiley   +1 more source

Innovative gene engineering strategies to address tumor antigen escape in cell therapy. [PDF]

J Transl Med
Chen Y, Niu S, Li YR, Yang L.
europepmc   +1 more source

Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]

HLA
Schenk HCM, Gille I, Arana C, Rovira J, Palou E, Diekmann F, Roelen DL, Heemskerk MHM, Heidt S.   +8 more
europepmc   +1 more source

Plasma Elastase Screening in Hematological Disease Reveals Its Potential as a Diagnostic and Prognostic Biomarker in Hematological Malignancies

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Neutrophil‐extracellular traps are net‐like material released by triggered neutrophils and composed of decondensed chromatin linked to nuclear proteins. Elastase, one of the fourth most represented neutrophil‐specific serine proteases stored in azurophil granules of naïve neutrophils, exerts various actions, including degradation ...
Pasqualina Scala, Anna Maria Della Corte, Angela Bertolini, Marisa Gorrese, Francesca Picone, Bianca Serio, Danilo De Novellis, Laura Mettivier, Luca Pezzullo, Maria Carmen Martorelli, Denise Morini, Matteo D'Addona, Bianca Cuffa, Carmine Selleri, Valentina Giudice   +14 more
wiley   +1 more source

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination. [PDF]

Eur J Immunol
Fernandez Blanco L, Kuijper LH, Kummer LYL, Verstegen NJM, Bos A, Claireaux M, Duurland MC, Jorritsma T, Steenhuis M, Kerster G, Vallejo JJG, van Gils MJ, van Dam KPJ, Stalman EW, Wieske L, Boekel L, Wolbink GJ, Tas SW, Rispens T, Kuijpers TW, Eftimov F, Brinke AT, van Ham SM, of T2B! Immunity Against SARS‐CoV‐2 Study Group.   +23 more
europepmc   +1 more source

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

CAR T Cell Therapy for Rheumatoid Arthritis. [PDF]

Clin Rev Allergy Immunol
Freeley M.
europepmc   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source

Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application. [PDF]

Front Oncol
Ren T, Wang F, Liu X, Guo J, Xie S.
europepmc   +1 more source